- Home
- HRTX vs AVTX Comparison
HRTX vs AVTX Comparison
Compare HRTX & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$1.28
HOLD
Current Price
$13.91
Company Overview
Basic Information| Metric | HRTX | AVTX |
|---|---|---|
| Founded | 1983 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 265.9M | 248.3M |
| IPO Year | 1987 | 2015 |
Fundamental Metrics
Financial Performance| Metric | HRTX | AVTX |
|---|---|---|
| Price | $1.28 | $13.91 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | $4.50 | ★ $34.50 |
| AVG Volume (30 Days) | ★ 1.5M | 369.7K |
| Earning Date | 02-26-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $155,097,000.00 | $192,000.00 |
| Revenue This Year | $8.98 | N/A |
| Revenue Next Year | $11.57 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 12.60 | N/A |
| 52 Week Low | $1.00 | $3.39 |
| 52 Week High | $2.68 | $20.72 |
Technical Indicators
Market Signals| Indicator | HRTX | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 43.85 | 39.22 |
| Support Level | $1.19 | $13.04 |
| Resistance Level | $1.42 | $16.15 |
| Average True Range (ATR) | 0.07 | 1.18 |
| MACD | -0.02 | -0.13 |
| Stochastic Oscillator | 30.65 | 19.51 |
Price Performance
Historical Comparison HRTX
AVTX
About HRTX Heron Therapeutics Inc.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).